Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy - a Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2013
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 Mar 2012 Planned End Date changed from 1 Dec 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 24 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Mar 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.